Abstract: A preparation method for a decellularized matrix biomaterial, which combines specific pretreatment, degreasing, disinfection, decellularization, ?-Gal antigen removal and sterilization, and reserves the integrity of bioactive components and structures in a material to the maximum extent while effectively removing an antigenic substance of an animal tissue, so that a decellularized matrix biomaterial having low immunogenicity and high biological activity is obtained. In addition, the decellularized matrix biomaterial prepared by the method effectively reduces immunogen components, has good biocompatibility and biological safety, is beneficial to cell adhesion, aggregation and proliferation on the surface, and can be used as a high-activity biological matrix material to be applied to skin soft tissue defect, gingival recession and periodontal soft tissue repair.

Abstract: The present disclosure relates to the technical field of Internet, in particular to a method for measuring network international outlet interfaces of a designated area. The method includes the following steps: acquiring a designated collection of routing interface paths and area location information of IP addresses of routing interface nodes; dividing the collected routing interface paths into critical hop complete paths and critical hop missing paths; determining whether a routing interface path is a critical hop complete path; using a 2-tuple to identify network international outlet interfaces of the routing interface path; and counting the quantity of the network international outlet interfaces of the measured area.

Abstract: A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.

Abstract: A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.

Abstract: The embodiments of the present invention provide a crushing cavity structure for the technical field of crushing cavities of cone crushing equipment.

Abstract: The embodiments of the present invention provide a crushing cavity structure for the technical field of crushing cavities of cone crushing equipment.

Abstract: The present disclosure discloses a multi-gradient structure-reinforced cone crusher and a design method of a lining plate thereof. The multi-gradient structure-reinforced cone crusher includes a movable cone and a fixed cone arranged around the movable cone, and a crushing cavity formed in the radial space between the fixed cone and the movable cone, the surfaces of the fixed cone and the movable cone that are opposite to each other are respectively provided with a fixed cone lining plate and a movable cone lining plate, the working faces of the fixed cone lining plate and the movable cone lining plate that face the crushing cavity are provided with multiple sets of cast-in alloy, which are different in at least one of distribution density, maximum size of exposed surface and shape of the cast-in alloy in a direction from the feed port to the discharge port.

Abstract: The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-?C46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-? protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-?. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-?C46A mutants.

Abstract: Among others, the present invention provides a blank liposome, preparation methods thereof, and a loaded liposome including the blank liposome and an active substance. The liposomes have a membrane comprising lipids and a ginsenoside of Formula I, and may further comprise a surfactant, a heat-sensitive excipient, a pH sensitive material, or an ion additive.

Abstract: A saponin nano micelle, preparing method, application and pharmaceutical composition thereof is disclosed in the present invention. The saponin nano micelle comprises one or more of saponins represented by formula 1, in which, R1 and R2 are independently —H or a hydrophilic group, R3 is —H or —OH, R4 is a lipophilic group. The preparing method of the saponin nano micelle is that mixing the saponin with an organic solvent which can dissolve saponin, and then removing the organic solvent. The saponin micelle acts as a convey medium of the drug ingredients, and can replace conventional drug carriers such as pharmaceutical solubilizers or polymeric micelle, which has high safety and great significance. The pharmaceutical ingredients can prolong circulation time and biological half-life of drug in the blood, and increase the accumulation of drug in lesions, and reduce adverse reactions.

Abstract: The present invention provides novel ginsenoside derivative compounds and the use thereof in protection against ischemia/reperfusion injury.

Abstract: The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-?C46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-? protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-?. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-?C46A mutants.

Abstract: A saponin nano micelle, preparing method, application and pharmaceutical composition thereof is disclosed in the present invention. The saponin nano micelle comprises one or more of saponins represented by formula 1, in which, R1 and R2 are independently —H or a hydrophilic group, R3 is —H or —OH, R4 is a lipophilic group. The preparing method of the saponin nano micelle is that mixing the saponin with an organic solvent which can dissolve saponin, and then removing the organic solvent. The saponin micelle acts as a convey medium of the drug ingredients, and can replace conventional drug carriers such as pharmaceutical solubilizers or polymeric micelle, which has high safety and great significance. The pharmaceutical ingredients can prolong circulation time and biological half-life of drug in the blood, and increase the accumulation of drug in lesions, and reduce adverse reactions.

Abstract: The present invention relates to a novel compound derived from ginsenoside Rh2, the preparation methods and the use thereof in treating cancers.

Abstract: The present invention provides novel ginsenoside derivative compounds and the use thereof in protection against ischemia/reperfusion injury.

Abstract: A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.

Abstract: Uses and applications derived from the discovery of a novel binding site of IKK-?, such as method of screening a therapeutic agent as drug candidate for treating cancer, inflammation, or other diseases/disorders, are provided.

Abstract: The present invention relates to a novel compound derived from ginsenoside Rh2, the preparation methods and the use thereof in treating cancers.

Abstract: Uses and applications derived from the discovery of a novel binding site of IKK-?, such as method of screening a therapeutic agent as drug candidate for treating cancer, inflammation, or other diseases/disorders, are provided.

Abstract: Two hitherto unreported novel hemiterpene glycosides were isolated in substantially pure form from the root of Ilex pubescens. The chemical structures and some properties of these hemiterpenes have been elucidated. These hemiterpene glycosides possess anti-platelet aggregation activity more potent than those of salvianolic acid B and aspirin and may be used in pharmaceutical compositions in humans and mammals in need of such treatment.